Coherus Oncology Inc
NASDAQ:CHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Coherus Oncology Inc
NASDAQ:CHRS
|
US |
|
M
|
MGM Resorts International
XMUN:MGG
|
US |
|
L
|
Lime Technologies AB (publ)
F:LTX
|
SE |
|
Schindler Holding AG
F:SHR
|
CH |
|
KRM22 PLC
LSE:KRM
|
UK |
|
A
|
Aecon Group Inc
F:2AE
|
CA |
|
O
|
Ollie's Bargain Outlet Holdings Inc
F:OL6
|
US |
|
Synergia Energy Ltd
LSE:SYN
|
AU |
|
STRABAG SE
VSE:STR
|
AT |
|
Almirall SA
MAD:ALM
|
ES |
Intrinsic Value
Is CHRS undervalued or overvalued?
See the intrinsic value estimate for Coherus Oncology Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CHRS looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with CHRS’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Coherus Oncology Does
Coherus BioSciences makes and sells biosimilar medicines and oncology drugs. Biosimilars are highly similar, lower-cost versions of complex biologic drugs made from living cells. Coherus focuses on products used by doctors, hospitals, clinics, and specialty pharmacies, especially in areas like cancer care and immune-related disease.
- Headquarters
- United States of America US
- Employees
- 147
- IPO date
- Nov 6, 2014
Revenue & Expenses Breakdown
Coherus Oncology Inc
Earnings Waterfall
Coherus Oncology Inc
The intrinsic value for Coherus Oncology Inc (CHRS) under the Base Case is hidden USD.
Compared with the current market price of 1.07 USD, the stock appears hidden.